Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agilon Health (AGL) EBITDA: 2020-2025

Historic EBITDA for Agilon Health (AGL) over the last 6 years, with Q3 2025 value amounting to -$127.5 million.

  • Agilon Health's EBITDA rose 224.99% to -$127.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$362.7 million, marking a year-over-year decrease of 758.82%. This contributed to the annual value of -$279.9 million for FY2024, which is 2489.46% down from last year.
  • According to the latest figures from Q3 2025, Agilon Health's EBITDA is -$127.5 million, which was up 224.99% from -$112.1 million recorded in Q2 2025.
  • Over the past 5 years, Agilon Health's EBITDA peaked at $2.1 million during Q1 2023, and registered a low of -$297.8 million during Q2 2021.
  • Over the past 5 years, Agilon Health's median EBITDA value was -$35.0 million (recorded in 2021), while the average stood at -$64.9 million.
  • In the last 5 years, Agilon Health's EBITDA plummeted by 3949614.36% in 2021 and then skyrocketed by 502325.58% in 2023.
  • Over the past 5 years, Agilon Health's EBITDA (Quarter) stood at -$25.7 million in 2021, then crashed by 106.0% to -$52.9 million in 2022, then crashed by 206.25% to -$161.9 million in 2023, then soared by 35.27% to -$104.8 million in 2024, then dropped by 21.64% to -$127.5 million in 2025.
  • Its EBITDA was -$127.5 million in Q3 2025, compared to -$112.1 million in Q2 2025 and -$18.3 million in Q1 2025.